{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:56:28Z","timestamp":1772794588690,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Most tools for estimating utilities use clinical trial data from general health status models, such as the 36-Item Short-Form Health Survey (SF-36). A disease-specific model may be more appropriate. The objective of this study was to apply a disease-specific utility mapping function for schizophrenia to data from a large, 1-year, open-label study of long-acting risperidone and to compare its performance with an SF-36-based utility mapping function.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with schizophrenia or schizoaffective disorder by DSM-IV criteria received 25, 50, or 75 mg long-acting risperidone every 2 weeks for 12 months. The Positive and Negative Syndrome Scale (PANSS) and SF-36 were used to assess efficacy and health-related quality of life. Movement disorder severity was measured using the Extrapyramidal Symptom Rating Scale (ESRS); data concerning other common adverse effects (orthostatic hypotension, weight gain) were collected. Transforms were applied to estimate utilities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 474 patients completed the study. Long-acting risperidone treatment was associated with a utility gain of 0.051 using the disease-specific function. The estimated gain using an SF-36-based mapping function was smaller: 0.0285. Estimates of gains were only weakly correlated (r = 0.2). Because of differences in scaling and variance, the requisite sample size for a randomized trial to confirm observed effects is much smaller for the disease-specific mapping function (156 versus 672 total subjects).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Application of a disease-specific mapping function was feasible. Differences in scaling and precision suggest the clinically based mapping function has greater power than the SF-36-based measure to detect differences in utility.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1477-7525-3-57","type":"journal-article","created":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T06:14:12Z","timestamp":1126592052000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia"],"prefix":"10.1186","volume":"3","author":[{"given":"Leslie A","family":"Lenert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia FT","family":"Rupnow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Elnitsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,9,11]]},"reference":[{"key":"208_CR1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/07853890109002092","volume":"33","author":"WJ Furlong","year":"2001","unstructured":"Furlong WJ, Feeny DH, Torrance GW, Barr RD: The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001, 33: 375\u2013384.","journal-title":"Ann Med"},{"key":"208_CR2","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/00005650-199607000-00004","volume":"34","author":"GW Torrance","year":"1996","unstructured":"Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q: Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 1996, 34: 702\u2013722. 10.1097\/00005650-199607000-00004","journal-title":"Med Care"},{"key":"208_CR3","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/bmj.316.7133.736","volume":"316","author":"P Kind","year":"1998","unstructured":"Kind P, Dolan P, Gudex C, Williams A: Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998, 316: 736\u2013741.","journal-title":"BMJ"},{"key":"208_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/intqhc\/10.6.509","volume":"10","author":"RM Kaplan","year":"1998","unstructured":"Kaplan RM, Ganiats TG, Sieber WJ, Anderson JP: The Quality of Well-Being Scale: critical similarities and differences with SF-36. Int J Qual Health Care 1998, 10: 509\u2013520. 10.1093\/intqhc\/10.6.509","journal-title":"Int J Qual Health Care"},{"key":"208_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"J Ware Jr","year":"1996","unstructured":"Ware J Jr, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34: 220\u2013233. 10.1097\/00005650-199603000-00003","journal-title":"Med Care"},{"key":"208_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30: 473\u2013483.","journal-title":"Med Care"},{"key":"208_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0272989X9701700101","volume":"17","author":"DG Fryback","year":"1997","unstructured":"Fryback DG, Lawrence WF, Martin PA, Klein R, Klein BE: Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med Decis Making 1997, 17: 1\u20139.","journal-title":"Med Decis Making"},{"key":"208_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/02729890122062352","volume":"21","author":"MB Nichol","year":"2001","unstructured":"Nichol MB, Sengupta N, Globe DR: Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36. Med Decis Making 2001, 21: 105\u2013112. 10.1177\/02729890122062352","journal-title":"Med Decis Making"},{"key":"208_CR9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1097\/01.mlr.0000135812.52570.42","volume":"42","author":"N Sengupta","year":"2004","unstructured":"Sengupta N, Nichol MB, Wu J, Globe D: Mapping the SF-12 to the HUI3 and VAS in a managed care population. Med Care 2004, 42: 927\u2013937. 10.1097\/01.mlr.0000135812.52570.42","journal-title":"Med Care"},{"key":"208_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","volume":"42","author":"JE Brazier","year":"2004","unstructured":"Brazier JE, Roberts J: The estimation of a preference-based measure of health from the SF-12. Med Care 2004, 42: 851\u2013859. 10.1097\/01.mlr.0000135827.18610.0d","journal-title":"Med Care"},{"key":"208_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","volume":"21","author":"J Brazier","year":"2002","unstructured":"Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002, 21: 271\u2013292. 10.1016\/S0167-6296(01)00130-8","journal-title":"J Health Econ"},{"key":"208_CR12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/00005650-200007000-00008","volume":"38","author":"LA Lenert","year":"2000","unstructured":"Lenert LA, Sherbourne CD, Sugar C, Wells KB: Estimation of utilities for the effects of depression from the SF-12. Med Care 2000, 38: 763\u2013770. 10.1097\/00005650-200007000-00008","journal-title":"Med Care"},{"key":"208_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00019053-199711020-00005","volume":"11","author":"JE Siegel","year":"1997","unstructured":"Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR: Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997, 11: 159\u2013168.","journal-title":"Pharmacoeconomics"},{"key":"208_CR14","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1097\/00005650-200111000-00011","volume":"39","author":"C Donald Sherbourne","year":"2001","unstructured":"Donald Sherbourne C, Unutzer J, Schoenbaum M, Duan N, Lenert LA, Sturm R, Wells KB: Can utility-weighted health-related quality-of-life estimates capture health effects of quality improvement for depression? Med Care 2001, 39: 1246\u20131259. 10.1097\/00005650-200111000-00011","journal-title":"Med Care"},{"key":"208_CR15","doi-asserted-by":"crossref","unstructured":"Kay SR, Opler LA, Lindenmayer JP: The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry 1989, (Suppl 7):59\u201367.","DOI":"10.1192\/S0007125000291514"},{"key":"208_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.schres.2003.11.008","volume":"71","author":"PE Mohr","year":"2004","unstructured":"Mohr PE, Cheng CM, Claxton K, Conley RR, Feldman JJ, Hargreaves WA, Lehman AF, Lenert LA, Mahmoud R, Marder SR, Neumann PJ: The heterogeneity of schizophrenia in disease states. Schizophr Res 2004, 71: 83\u201395. 10.1016\/j.schres.2003.11.008","journal-title":"Schizophr Res"},{"key":"208_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.schres.2003.10.010","volume":"71","author":"LA Lenert","year":"2004","unstructured":"Lenert LA, Sturley AP, Rapaport MH, Chavez S, Mohr PE, Rupnow M: Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004, 71: 155\u2013165. 10.1016\/j.schres.2003.10.010","journal-title":"Schizophr Res"},{"key":"208_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2165\/00044011-200424050-00004","volume":"24","author":"RA Mahmoud","year":"2004","unstructured":"Mahmoud RA, Engelhart LM, Janagap CC, Oster G, Ollendorf D: Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care. Clin Drug Invest 2004, 24: 275\u2013286.","journal-title":"Clin Drug Invest"},{"key":"208_CR19","first-page":"440","volume-title":"Proceedings of the 2002 AMIA Annual Symposium: 9\u201313 November 2002; San Antonio","author":"LA Lenert","year":"2002","unstructured":"Lenert LA, Sturley AE: Use of the Internet to study the utility values of the public. In Proceedings of the 2002 AMIA Annual Symposium: 9\u201313 November 2002; San Antonio. Edited by: Kohane IS. Bethesda: AMIA; 2002:440\u2013444."},{"key":"208_CR20","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.4088\/JCP.v64n1017","volume":"64","author":"WW Fleischhacker","year":"2003","unstructured":"Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O: Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003, 64: 1250\u20131257.","journal-title":"J Clin Psychiatry"},{"key":"208_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jad.2004.05.008","volume":"83","author":"R Lasser","year":"2004","unstructured":"Lasser R, Bossie CA, Gharabawi G, Eerdekens M, Nasrallah HA: Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord 2004, 83: 263\u2013275. 10.1016\/j.jad.2004.05.008","journal-title":"J Affect Disord"},{"key":"208_CR22","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association; 1994.","edition":"4"},{"key":"208_CR23","first-page":"233","volume":"7","author":"G Chouinard","year":"1980","unstructured":"Chouinard G, Ross-Chouinard A, Annable L, Jones BD: Extrapyramidal symptom rating scale. Can J Neurolog Sci 1980, 7: 233.","journal-title":"Can J Neurolog Sci"},{"key":"208_CR24","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J: Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale, New Jersey: Lawrence Erlbaum Associates; 1988.","edition":"2"},{"key":"208_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/01.mlr.0000108748.13206.ba","volume":"42","author":"CA Sugar","year":"2004","unstructured":"Sugar CA, James GM, Lenert LA, Rosenheck RA: Discrete state analysis for interpretation of data from clinical trials. Med Care 2004, 42: 183\u2013196. 10.1097\/01.mlr.0000108748.13206.ba","journal-title":"Med Care"},{"key":"208_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1023\/A:1023453405252","volume":"12","author":"EA Stolk","year":"2003","unstructured":"Stolk EA, Busschbach JJ: Validity and feasibility of the use of condition-specific outcome measures in economic evaluation. Qual Life Res 2003, 12: 363\u2013371. 10.1023\/A:1023453405252","journal-title":"Qual Life Res"},{"key":"208_CR27","first-page":"1237","volume":"33","author":"R Rosenheck","year":"1998","unstructured":"Rosenheck R, Cramer J, Xu W, Grabowski J, Douyon R, Thomas J, Henderson W, Charney D: Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Health Serv Res 1998, 33: 1237\u20131261.","journal-title":"Health Serv Res"},{"key":"208_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/00005650-200302000-00003","volume":"41","author":"JM Pyne","year":"2003","unstructured":"Pyne JM, Sullivan G, Kaplan R, Williams DK: Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia. Med Care 2003, 41: 208\u2013217. 10.1097\/00005650-200302000-00003","journal-title":"Med Care"},{"key":"208_CR29","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJM199709183371202","volume":"337","author":"R Rosenheck","year":"1997","unstructured":"Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D: A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997, 337: 809\u2013815. 10.1056\/NEJM199709183371202","journal-title":"N Engl J Med"},{"key":"208_CR30","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","volume":"290","author":"R Rosenheck","year":"2003","unstructured":"Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V, Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003, 290: 2693\u20132702. 10.1001\/jama.290.20.2693","journal-title":"JAMA"},{"key":"208_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/0272989X02239649","volume":"23","author":"LA Lenert","year":"2003","unstructured":"Lenert LA, Sturley A, Rupnow M: Toward improved methods for measurement of utility: automated repair of errors in elicitations. Med Decis Making 2003, 23: 67\u201375. 10.1177\/0272989X02239649","journal-title":"Med Decis Making"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7525-3-57.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T23:02:24Z","timestamp":1630450944000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/1477-7525-3-57"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,11]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["208"],"URL":"https:\/\/doi.org\/10.1186\/1477-7525-3-57","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,11]]},"assertion":[{"value":"15 June 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"57"}}